Truncation variants of BCR-ABL mRNA that produces BCR-ABL proteins with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is described. Vectors for expressing the truncated gene products are described as well as recombinant cells that express the truncated gene products from cDNA constructs. Also provided are methods compositions and kits for detecting the BCR-ABL truncation variants. Also provided are methods for determining the prognosis of a patient diagnosed as having myeloproliferative disease, and methods for predicting the likelihood for resistance to a treatment with tyrosine kinase inhibitor in a patient diagnosed as having myeloproliferative disease. Additionally, methods for screening BCR-ABL tyrosine kinase domain inhibitors which rely on the recombinant cells are also disclosed.

Embodiments herein provide methods for identifying antibody glycosylation profiles which correlate with antibody effector functions. These profiles are antibody signatures for the respective correlated antibody effector functions, and are incorporated into engineered antibody for antibody-mediated treatments of infections, diseases, and medical conditions.

Assays and methods for diagnosing and treating autoimmune diseases. Particularly, the invention provides methods for differential diagnosis of specific autoimmune diseases, including autoimmune rheumatic disorders.

The present application is in the field of sialic acid biochemistry, metabolism and antigenicity. More particularly, the present invention relates to the detection and analysis of Siglec-XII in a human biological sample for risk prediction, prognostication and diagnosis of disease. Also provided are devices configured to perform the methods disclosed herein.

Disclosed herein are compositions including reagents for detecting human autoantibodies against at least two proteins selected from the group consisting of A1AT, ANGPTL4, LRP10, GFRA1, LGALS3, CST2, DKK1, CAPC, GRP78, and GRN, wherein at least one of the antibody detection markers is selected from the group consisting of A1AT, LGALS3, and CAPC, and their use in monitoring efficacy of breast cancer therapy and breast cancer recurrence.

Assays and methods for diagnosing and treating autoimmune diseases. Particularly, the invention provides methods for differential diagnosis of specific autoimmune diseases, including autoimmune rheumatic disorders.

Methods for prognosing the risk of progression in a ER-positive breast cancer (e.g., luminal B 1 breast cancer) subject are provided, such methods including the detection of levels of a variety of biomarkers prognostic of progression. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

Embodiments of this invention include methods for detecting in vitro the presence in peripheral blood mononuclear cells (PBMCs), and in serum or plasma, of antibodies reactive to and of lymphocytes that are responsive to CNS antigens associated with Multiple Sclerosis (MS). These CNS antigens include, but are not limited to whole brain lysate and the myelin antigens myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), MOG peptides (MOGps), proteolipid protein (PLP), and PLP peptides (PLPps). PBMCs obtained from patients with active MS produce antibodies specific for CNS antigen, and causes T-lymphocytes to produce T-lymphocyte-specific cytokines, including interferon gamma (IFN-), interleukin-2 (IL-2), or interleukin-17 (IL-17). In contrast, PBMCs from subjects without MS do not produce such responses. The magnitude of the CNS antigen-specific response in patients with definite MS or in patients with CIS or RIS can indicate the likelihood that a given patient will develop a relapse and can indicate the responsiveness to and the success of immune modulatory treatment.

Methods and apparatuses for athletic performance monitoring with body synchronization analysis are disclosed. In one example, a first sensor output associated with a movement of an user foot and a second sensor output associated with a movement of an user arm are received, the user arm on a body side opposite the user foot. The first sensor output and the second sensor output are analyzed to identify a degree of synchronization between the movement of a user foot and the movement of a user arm.

The present invention relates to a method for assisting recurrence risk prediction for hepatocellular carcinoma patients. The method comprises measuring glypican 3 (GPC3) peptide recognized by both a first monoclonal antibody and a second monoclonal antibody in a blood sample of a hepatocellular carcinoma patient, by contacting the sample with the first monoclonal antibody that recognizes a peptide having an amino acid sequence in the N-terminal side of GPC3 and the second monoclonal antibody that recognizes a peptide having an amino acid sequence in the C-terminal side of GPC3, and detecting the complex comprising GPC3 peptide, the first antibody and the second antibody.